JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Overview
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
JAZZ Key Statistics, Chart & Performance
The current stock price of JAZZ is 127.491 USD. In the past month the price increased by 0.69%. In the past year, price increased by 14.49%.
JAZZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.75 | 684.07B | ||
| JNJ | JOHNSON & JOHNSON | 18.06 | 434.92B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.2 | 246.08B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.02 | 240.18B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.71 | 230.06B | ||
| MRK | MERCK & CO. INC. | 10.16 | 195.40B | ||
| PFE | PFIZER INC | 7.01 | 135.17B | ||
| SNY | SANOFI-ADR | 10.33 | 111.58B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.57 | 90.00B | ||
| GSK | GSK PLC-SPON ADR | 9.13 | 82.41B | ||
| ZTS | ZOETIS INC | 23.08 | 63.61B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.53 | 46.28B |
Related stock screener links
About JAZZ
Company Profile
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. The company is headquartered in Dublin, Dublin and currently employs 2,800 full-time employees. The company went IPO on 2012-01-18. The company is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Company Info
JAZZ PHARMACEUTICALS PLC
Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4
DUBLIN DUBLIN D04 IE
CEO: Bruce C. Cozadd
Employees: 2800
Phone: 35316347800
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
What is the stock price of JAZZ PHARMACEUTICALS PLC today?
The current stock price of JAZZ is 127.491 USD. The price increased by 0.39% in the last trading session.
What is the ticker symbol for JAZZ PHARMACEUTICALS PLC stock?
The exchange symbol of JAZZ PHARMACEUTICALS PLC is JAZZ and it is listed on the Nasdaq exchange.
On which exchange is JAZZ stock listed?
JAZZ stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JAZZ PHARMACEUTICALS PLC stock?
25 analysts have analysed JAZZ and the average price target is 190.45 USD. This implies a price increase of 49.39% is expected in the next year compared to the current price of 127.491. Check the JAZZ PHARMACEUTICALS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JAZZ PHARMACEUTICALS PLC worth?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a market capitalization of 7.73B USD. This makes JAZZ a Mid Cap stock.
How many employees does JAZZ PHARMACEUTICALS PLC have?
JAZZ PHARMACEUTICALS PLC (JAZZ) currently has 2800 employees.
What are the support and resistance levels for JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a support level at 125.22 and a resistance level at 127.94. Check the full technical report for a detailed analysis of JAZZ support and resistance levels.
Is JAZZ PHARMACEUTICALS PLC (JAZZ) expected to grow?
The Revenue of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to grow by 4.32% in the next year. Check the estimates tab for more information on the JAZZ EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JAZZ, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JAZZ, evaluating the profitability, health, valuation and growth aspects
- JAZZ PHARMACEUTICALS PLC (JAZZ) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JAZZ PHARMACEUTICALS PLC (JAZZ) Sales and EPS estimates to see what analysts future expectations are.
- JAZZ PHARMACEUTICALS PLC (JAZZ) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JAZZ PHARMACEUTICALS PLC (JAZZ) Insider and Institutional Ownership to learn about the owners and their transactions.
- JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Chart to make your own analysis
- JAZZ PHARMACEUTICALS PLC (JAZZ) Latest news and press-releases to stay up to date.
Does JAZZ PHARMACEUTICALS PLC (JAZZ) stock pay dividends?
JAZZ does not pay a dividend.
When does JAZZ PHARMACEUTICALS PLC (JAZZ) report earnings?
JAZZ PHARMACEUTICALS PLC (JAZZ) will report earnings on 2025-11-04, after the market close.
What is the Price/Earnings (PE) ratio of JAZZ PHARMACEUTICALS PLC (JAZZ)?
The PE ratio for JAZZ PHARMACEUTICALS PLC (JAZZ) is 19.2. This is based on the reported non-GAAP earnings per share of 6.64 and the current share price of 127.491 USD. Check the full fundamental report for a full analysis of the valuation metrics for JAZZ.
What is the Short Interest ratio of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
The outstanding short interest for JAZZ PHARMACEUTICALS PLC (JAZZ) is 9.72% of its float. Check the ownership tab for more information on the JAZZ short interest.
JAZZ Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to JAZZ. When comparing the yearly performance of all stocks, JAZZ is one of the better performing stocks in the market, outperforming 77.42% of all stocks.
JAZZ Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ. There are concerns on the financial health of JAZZ while its profitability can be described as average.
JAZZ Financial Highlights
Over the last trailing twelve months JAZZ reported a non-GAAP Earnings per Share(EPS) of 6.64. The EPS decreased by -62.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.7% | ||
| ROE | -10.92% | ||
| Debt/Equity | 1.17 |
JAZZ Forecast & Estimates
25 analysts have analysed JAZZ and the average price target is 190.45 USD. This implies a price increase of 49.39% is expected in the next year compared to the current price of 127.491.
For the next year, analysts expect an EPS growth of -74.63% and a revenue growth 4.32% for JAZZ